In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.

Pérez-Trallero, Emilio; Marimón, José María; González, Alberto; Ercibengoa, María; Larruskain, Julián · Clin Infect Dis · 2005

case_series · Level IV

Where this comes from

Abstract

Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment. The development of high-level levofloxacin resistance (i.e., a minimum inhibitory concentration >8 mu g/mL) in 8 patients whose previous pneumococcal isolates showed susceptibility is described. Molecular methods were used to characterize the strains and to study the sequential changes in fluoroquinolone targets.

Medical subject headings